Adverse effects in children after unintentional buprenorphine exposure

Pediatrics

Volumn 118, Issue 4, 2006, Pages 1746-1751

  Geib, Ann Jeannette ^a,c   Babu, Kavita ^b   Ewald, Michele Burns ^a   Boyer, Edward W ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Harrisburg Hospital   (United States)

Author keywords

Buprenorphine; Exploratory behavior; Opioid; Pediatric; Respiratory depression; Unintentional ingestion

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; NALOXONE; OPIATE; OPIATE ANTAGONIST; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; BIOAVAILABILITY; CHILD HEALTH CARE; CLINICAL ARTICLE; CLINICAL FEATURE; DEPRESSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HEART RATE; HOSPITAL ADMISSION; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATION DEPRESSION; TABLET; TODDLER; UNITED STATES; URINALYSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; CONSCIOUSNESS DISORDER; INFANT; INTOXICATION; RESPIRATORY FAILURE;

ANALGESICS, OPIOID; BUPRENORPHINE; CONSCIOUSNESS DISORDERS; FEMALE; HUMANS; INFANT; MALE; NALOXONE; NARCOTIC ANTAGONISTS; POISONING; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY;

EID: 33750103198     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0948     Document Type: Article

References (40)

1. Cook S, Indig D, Gray J, McGrath D. Opiate overdose and health treatment options for opiate users in New South Wales, 1999-2002. N S W Public Health Bull. 2004;15:125-131
2. Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand. 2003;47:1031-1033
3. Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45:226-228
4. Gueye PN, Megarbane B, Borron SW, et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction. 2002;97:1295-1304
5. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001;121:65-69
6. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002;35:513-516
7. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol. 1998;22:430-434
8. Doyon S, Klein-Schwartz W, Welsh C. Toxicity following buprenorphine ingestions. Clin Toxicol. 2005;43:640
9. Gaulier JM, Charvier F, Monceaux F, Marquet P, Lachatre G. Ingestion of high-dose buprenorphine by a 4 year-old child. J Toxicol Clin Toxicol. 2004;42:993-995
10. Spadari M, Arditti J, Affaton MF, David JM, Valli M. Accidental narcotic and buprenorphine poisoning in children notified at the Marseille Poison Center between 1993 and 1999 [in French] [published correction appears in Therapie. 2001;56:73]. Therapie. 2000;55:705-708
11. Brooks DE, Roberge RJ, Spear A. Clinical nuances of pediatric methadone intoxication. Vet Hum Toxicol. 1999;41:388-390
12. Schwab J, Caggiano AO. Pediatric methadone poisoning revisited. Clin Pediatr (Phila). 2001;40:119-120
13. Hardwick WE Jr, King WD, Palmisano PA. Respiratory depression in a child unintentionally exposed to transdermal fentanyl patch. South Med J. 1997;90:962-963
14. Hoffman RJ, Nelson LS, Hoffman RS. Life-threatening levo-a-acetylmethadol (LAAM) overdose. J Toxicol Clin Toxicol. 2000;38:188-189
15. Horowitz R, Mazor SS, Aks SE, Leikin JB. Accidental clonidine patch ingestion in a child. Am J Ther. 2005;12:272-274
16. Kraft ME. A 9-month-old with bradycardia and periodic apnea. J Emerg Nurs. 1998;24:457-459
17. Chiang NC, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(suppl):S39-S47
18. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20:369-378
19. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979;17:81-110
20. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981;12:117-122
21. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43:580-584
22. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther. 1997;281:428-433
23. Suboxone (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets)/Subutex (buprenorphine HCl sublingual tablets) [prescribing information]. Richmond, VA; Reckitt Benckiser Pharmaceuticals, Inc; 2005
24. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000;61:85-94
25. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003;70(suppl):S29-S37
26. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 suppl):S13-S27
27. Olkkola KT, Leijala MA, Maunuksela EL. Paediatric ventilatory effects of morphine and buprenorphine revisited. Paediatr Anaesth. 1995;5:303-305
28. Megarbane B, Marie N, Pirnay S, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006;212:256-267
29. Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003;(133):3-8; discussion 23-24
30. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther. 1989;45:66-71
31. Knape JT. Early respiratory depression resistant to naloxone following epidural buprenorphine. Anesthesiology. 1986;64:382-384
32. Thorn SE, Rawal N, Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet. 1988;1(8578):179-180
33. McCarron MM, Challoner KR, Thompson GA. Diphenoxylateatropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature). Pediatrics. 1991;87:694-700
34. Lewis JM, Klein-Schwartz W, Benson BE, Oderda GM, Takai S. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child. 1984;138:944-946
35. Gourlay GK, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. Br J Clin Pharmacol. 1983;15:269-271
36. Subcommittee on Pediatric Resuscitation. Toxicology. In: American Heart Association, ed. PALS Provider Manual. Dallas, TX: American Heart Association; 2002:319-321
37. Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15:566-570
38. Jain PN, Shah SC. Respiratory depression following combination of epidural buprenorphine and intramuscular ketorolac. Anaesthesia. 1993;48:898-899
39. McQuay HJ, Bullingham RE, Bennett MR, Moore RA. Delayed respiratory depression: a case report and a new hypothesis. Acta Anaesthesiol Belg. 1979;30(suppl):245-247
40. Simpson D, Braithwaite RA, Jarvie DR, et al. Screening for drugs of abuse (II): cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Ann Clin Biochem. 1997;34:460-510